Table 2.
Frequency of aCL and aβ2GPI in patients with RA and in the control group
| Autoantibodies | RA patients (n = 90) | Control group (n = 90) | P |
|---|---|---|---|
| aPL (aCL or aβ2GPI) |
35.5% (32/90) |
11.1% (10/90) |
.0001 |
| aCL (IgG, IgA or IgM) |
15.5%**** (14/90) |
5.5% (5/90) |
.04 |
| aCL‐IgG |
8.9% (8/90) |
2.2% (2/90) |
NS |
| aCL‐IgA |
4.4% * (4/90) |
2.2% (2/90) |
NS |
| aCL‐IgM |
6.7% (6/90) |
4.4% (4/90) |
NS |
| aβ2GPI (IgG, IgA, or IgM) |
32.2%**** (29/90) |
11.1% (10/90) |
.0005 |
| aβ2GPI‐IgG |
6.7%** (6/90) |
3.3% (3/90) |
NS |
| aβ2GPI‐IgA |
(24/90) |
7.8% (7/90) |
.0007 |
| aβ2GPI‐IgM |
5.6%*** (5/90) |
4.4% (4/90) |
NS |
*
Comparison between aCL‐IgA and aβ2GPI‐IgA (P = .00005).
**
Comparison between aβ2GPI‐IgG and aβ2GPI‐IgA (P = .0003).
***
Comparison between aβ2GPI‐IgM and aβ2GPI‐IgA (P = .0001).
****
Comparison between aCL and aβ2GPI (P = .008).